Drugs / TMZ
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03190967 | Apr 2018 → Jun 2021 | breast cancer, metastatic malignant neoplasm in the brain | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03190967 ↗ |
| Route | Oral | “TMZ was given orally daily in a 3+3 phase I dose escalation design at 30, 40, or 50 mg/m2, continuously.” PMID 36705597 ↗ Apr 2023 |